PD-L1 testing and immunotherapy selection - early laboratory experience and its potential role in head and neck cancer management
{{output}}
Anti-programmed cell death protein-1 (PD-1) therapy has been relatively recently approved in a defined context by NICE in adults in the management of recurrent and metastatic head and neck squamous cell carcinomas (HNSCC). In this context, companion diagnostic... ...
